Zeltia Chairman Sees FDA Approving Yondelis for Cancer Next Year
This article is for subscribers only.
Zeltia SA, the Spanish developer of cancer drugs from sea creatures, expects its Yondelis drug to be approved in the U.S. next year to treat relapsed ovarian cancer.
Centocor Ortho Biotech Products LP, Zeltia’s U.S. partner, is close to completing the collection of patient survival data the Food and Drug Administration demanded last year, Zeltia Chairman Jose Maria Fernandez Sousa-Faro said in a telephone interview. Centocor is a unit of Johnson & Johnson.